COMMUNIQUÉS West-GlobeNewswire

Neutra Corp Targets Expanded Sponsor and CRO Relationships in Q3 & Q4 2026, Reaffirming Full Commitment to Life Sciences Growth
13/07/2026
HOUSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Neutra Corp (OTC: NTRR), a company focused on health, wellness, and life sciences, today announced its forward-looking strategy for the third and fourth quarters of 2026, [...]
Cosmos Health Share Buyback Reaches 4.36 Million Shares; Continues Open Market Repurchases
13/07/2026
CHICAGO, July 13, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an [...]
GutGlucose Releases Latest Ingredients List with Gut Glucose Reset Formula
13/07/2026
Ceylon Cinnamon, Berberine HCl, Banaba Leaf Extract, Saffron, and Fucoxanthin Explained in the GutGlucose Daily Chewable Tablet Formula Largo, FL, July 13, 2026 (GLOBE NEWSWIRE) -- These statements have not been [...]
Cosmos Health Accelerates Prescription Medicine Strategy with Libytec Partnership to Commercialize DIABIT-IS X in Greece
13/07/2026
Cosmos Health will supply DIABIT-IS X (sitagliptin), while Libytec handles distribution and promotion in Greece Five-year agreement expected to contribute to revenue and cash-flow visibility As a prescription medicine, [...]
BreathEaseX Releases Sublingual Lung Health Spray with CardioEaseX Formula for Easy Breathing Support
13/07/2026
All Ten Ingredients: NAC, Quercetin, Manuka Honey, Vitamin D3, Olive Leaf, L-Theanine, CoQ10, Hawthorn Berry, L-Carnitine, and Magnesium Explained Aurora, CO, July 13, 2026 (GLOBE NEWSWIRE) -- These statements have not [...]
Zelluna doses first solid tumour patient with ZI-MA4-1 in the ZIMA-101 Phase 1 trial
13/07/2026
First patient dosed with ZI-MA4-1 in the ZIMA-101 Phase 1 trial at The Christie NHS Foundation Trust ZI-MA4-1 is the world’s first MAGE-A4-targeting TCR-NK therapy in clinical development ZIMA-101 represents the first [...]
Acentra Health Appoints Michael Kingston as Chief Digital & Information Officer to Lead Technology and AI Innovation
13/07/2026
New executive leadership role to accelerate innovation, modernize technology, and advance the company's long-term growth strategy MCLEAN, Va., July 13, 2026 (GLOBE NEWSWIRE) -- Acentra Health , a technology and health [...]
Sienna Senior Living Named One of Canada's Best Companies by TIME and Statista for Second Consecutive Year
13/07/2026
MARKHAM, Ontario, July 13, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. ("Sienna" or the "Company") is proud to announce it has been named one of Canada's Best Companies by TIME and Statista for the second [...]
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
13/07/2026
Company announcement No. 32 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 28, 2026) Copenhagen, Denmark, July 13, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: [...]
BrewDog Waterloo to Host England's Biggest Pub Watch Party for Blockbuster Semifinal
13/07/2026
England’s biggest pub comes alive for a blockbuster semifinal, delivering the atmosphere, the passion and an unforgettable football watch party as fans rally behind England LONDON, July 13, 2026 (GLOBE NEWSWIRE) -- [...]
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
13/07/2026
Selected as one of three late-breakthrough abstracts: clinical trials and innovation in thrombosis, CAD-1005 took center stage before the global thrombosis community at the largest ISTH meeting in more than a decade. [...]
Fortrea Announces Date for Second Quarter 2026 Financial Results and Conference Call
13/07/2026
DURHAM, N.C., July 13, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its second quarter 2026 financial [...]
Immutep Provides Clinical Update in 1st line NSCLC: Positive Mature Overall Survival Data from INSIGHT-003 and Update from TACTI-004
13/07/2026
INSIGHT-003 demonstrates mature mOS of 30.9 months in both the overall population (N=51) and patients with TPS <50% (N=47) in 1L non-squamous NSCLC Outcomes continue to compare favourably with historical benchmarks [...]
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial
13/07/2026
Principal Investigators of the Ongoing Phase I/II a Trial Highlighted Positive Early Experience with Clearmind Medicine’s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026 (GLOBE [...]
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026
13/07/2026
- Data presented as Developing Topics poster at AAIC 2026 - LEXINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to [...]
Oncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial
13/07/2026
Half of planned clinical sites will be activated this month; more than 20 patients have been pre-identified across participating centers Company to hold Type D meeting with FDA to discuss a potential registrational [...]
Novo Nordisk A/S - share repurchase programme
13/07/2026
Bagsværd, Denmark, 13 July 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) [...]
Enovis™ Companion Animal Health Launches CT-RevitL™, the Next-Generation Laser Therapy System for Veterinary Care
13/07/2026
CT-RevitL™ launches in the United States, built on a foundation of 150+ published studies on photobiomodulation (PBM) therapy Designed to deliver deeper, faster and more consistent therapeutic outcomes for animals [...]
Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development
13/07/2026
Physician-scientist and immunology leader joins Cue as the company advances key clinical programs in allergic and autoimmune diseases BOSTON, July 13, 2026 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a [...]

Pages